title: [Isolation rate of Enterococcus spp. from surgical infections and their susceptibilities].
abstract: Enterococcus spp. isolated from surgical infections during the period from July 1982 to June 1995 were investigated in a multicenter study involving 19 hospitals in Japan, and the following results were obtained. 1. Though the isolation rate of Enterococcus faecalis and other Enterococcus spp. were not high from primary infections, and from postoperative infections the isolation rate of other Enterococcus spp. was also low, the isolation rate of E. faecalis was highest from postoperative infections after 1993. 2. Vancomycin (VCM) showed strongest activity against E. faecalis, and followed by those of ampicillin (ABPC), imipenem. levofloxacin (LVFX) and meropenem in this order. Against other Enterococcus spp., VCM showed strongest activity, and followed by those of ABPC and LVFX. There were no resistant strains against VCM.
authors.affiliation: Department of Surgery, Nagoya City Koseiin Hospital.
authors.forename: N
authors.initials: N
authors.lastname: Shinagawa
authors.forename: H
authors.initials: H
authors.lastname: Koide
authors.forename: J
authors.initials: J
authors.lastname: Yura
authors.forename: T
authors.initials: T
authors.lastname: Manabe
authors.forename: K
authors.initials: K
authors.lastname: Mashita
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
authors.forename: A
authors.initials: A
authors.lastname: Mizuno
authors.forename: A K
authors.initials: AK
authors.lastname: Hirata
authors.forename: R
authors.initials: R
authors.lastname: Denno
authors.forename: M
authors.initials: M
authors.lastname: Mukaiya
authors.forename: K
authors.initials: K
authors.lastname: Ishibiki
authors.forename: Y
authors.initials: Y
authors.lastname: Ushijima
authors.forename: N
authors.initials: N
authors.lastname: Aikawa
authors.forename: K
authors.initials: K
authors.lastname: Takuma
authors.forename: S
authors.initials: S
authors.lastname: Iwai
authors.forename: M
authors.initials: M
authors.lastname: Kunimatsu
authors.forename: K
authors.initials: K
authors.lastname: Ohtsuka
authors.forename: H
authors.initials: H
authors.lastname: Kinoshita
authors.forename: K
authors.initials: K
authors.lastname: Morimoto
authors.forename: M
authors.initials: M
authors.lastname: Fujimoto
authors.forename: H
authors.initials: H
authors.lastname: Tanimura
authors.forename: H
authors.initials: H
authors.lastname: Ohnishi
authors.forename: Y
authors.initials: Y
authors.lastname: Umemoto
authors.forename: S
authors.initials: S
authors.lastname: Sakaguchi
authors.forename: R
authors.initials: R
authors.lastname: Ishihara
mesh_terms: D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D064704:Levofloxacin; D015242:Ofloxacin / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D013530:Surgical Wound Infection / Q000382:microbiology*; D013845:Thienamycins / Q000494:pharmacology; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D010406:Penicillins; D013845:Thienamycins; D064704:Levofloxacin; D014640:Vancomycin; D015378:Imipenem; D000667:Ampicillin; D015242:Ofloxacin